Small molecule allosteric modulation of the adenosine A₁ receptor

Area of Science:

• Pharmacology
• Neuroscience
• Cardiovascular Science

Background:

• G protein-coupled receptors (GPCRs) are key drug targets, with adenosine receptors (ARs) playing significant physiological roles.
• The adenosine A1 receptor (A1R) is implicated in cardiovascular and nervous system functions, making it a target for conditions like ischemia, epilepsy, and pain.
• Current A1R therapeutics (orthosteric ligands) face clinical trial challenges due to dose-limiting side effects.

Purpose of the Study:

• To review the adenosine A1 receptor (A1R) as a therapeutic target.
• To highlight advances in the structural understanding of A1R allosteric modulation.
• To explore the potential of allosteric modulators for A1R-related conditions.

Main Methods:

• Literature review focusing on A1R pharmacology and structural biology.
• Analysis of recent studies on allosteric modulators of A1R.
• Examination of clinical trial data for A1R-targeting drugs.

Main Results:

• Allosteric modulators offer a strategy to overcome limitations of orthosteric A1R ligands.
• Optimized allosteric ligands can achieve high subtype, spatial, and temporal selectivity for A1R.
• Structural insights are advancing the development of novel A1R allosteric modulators.

Conclusions:

• Adenosine A1 receptor (A1R) allosteric modulation presents a promising therapeutic avenue.
• This approach may lead to safer and more effective treatments for cardiovascular and neurological disorders.
• Further research into A1R allosteric modulators holds significant therapeutic potential.